Name | Number of supported studies | Average coverage | |
---|---|---|---|
adipocyte | 9 studies | 54% ± 14% | |
classical monocyte | 5 studies | 20% ± 4% |
Insufficient scRNA-seq data for expression of MTARC1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 95% | 1580.45 | 233 / 245 | 100% | 33.13 | 502 / 502 |
liver | 99% | 3112.89 | 223 / 226 | 92% | 11.05 | 375 / 406 |
thymus | 100% | 4117.33 | 653 / 653 | 91% | 12.03 | 550 / 605 |
brain | 92% | 884.16 | 2419 / 2642 | 91% | 6.48 | 645 / 705 |
intestine | 94% | 1102.47 | 904 / 966 | 85% | 5.35 | 447 / 527 |
bladder | 95% | 786.62 | 20 / 21 | 76% | 4.24 | 385 / 504 |
breast | 94% | 7143.15 | 431 / 459 | 77% | 4.22 | 859 / 1118 |
stomach | 82% | 613.72 | 295 / 359 | 72% | 3.69 | 207 / 286 |
lung | 78% | 956.68 | 450 / 578 | 65% | 4.29 | 756 / 1155 |
adrenal gland | 82% | 610.72 | 212 / 258 | 59% | 2.58 | 136 / 230 |
esophagus | 70% | 516.24 | 1012 / 1445 | 55% | 2.61 | 101 / 183 |
ovary | 53% | 332.56 | 96 / 180 | 68% | 2.93 | 293 / 430 |
kidney | 69% | 605.91 | 61 / 89 | 51% | 2.05 | 459 / 901 |
ureter | 0% | 0 | 0 / 0 | 100% | 4.75 | 1 / 1 |
adipose | 100% | 8998.68 | 1202 / 1204 | 0% | 0 | 0 / 0 |
pancreas | 53% | 331.93 | 174 / 328 | 46% | 1.76 | 81 / 178 |
uterus | 17% | 97.77 | 29 / 170 | 80% | 4.82 | 367 / 459 |
spleen | 88% | 1019.32 | 211 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 80% | 834.21 | 1073 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 73% | 3768.49 | 676 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 60% | 2.26 | 27 / 45 |
eye | 0% | 0 | 0 / 0 | 55% | 2.30 | 44 / 80 |
heart | 35% | 253.21 | 300 / 861 | 0% | 0 | 0 / 0 |
muscle | 34% | 212.56 | 270 / 803 | 0% | 0 | 0 / 0 |
skin | 16% | 139.12 | 281 / 1809 | 16% | 0.75 | 77 / 472 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0070458 | Biological process | cellular detoxification of nitrogen compound |
GO_0042126 | Biological process | nitrate metabolic process |
GO_0006809 | Biological process | nitric oxide biosynthetic process |
GO_0051410 | Biological process | detoxification of nitrogen compound |
GO_1903958 | Cellular component | nitric-oxide synthase complex |
GO_0005741 | Cellular component | mitochondrial outer membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0050421 | Molecular function | nitrite reductase (NO-forming) activity |
GO_0016661 | Molecular function | oxidoreductase activity, acting on other nitrogenous compounds as donors |
GO_0098809 | Molecular function | nitrite reductase activity |
GO_0043546 | Molecular function | molybdopterin cofactor binding |
GO_0005515 | Molecular function | protein binding |
GO_0030170 | Molecular function | pyridoxal phosphate binding |
GO_0030151 | Molecular function | molybdenum ion binding |
GO_0008940 | Molecular function | nitrate reductase activity |
Gene name | MTARC1 |
Protein name | Mitochondrial amidoxime reducing component 1 Mitochondrial amidoxime-reducing component 1 (mARC1) (EC 1.7.-.-) (Molybdenum cofactor sulfurase C-terminal domain-containing protein 1) (MOSC domain-containing protein 1) (Moco sulfurase C-terminal domain-containing protein 1) |
Synonyms | MARC1 MOSC1 |
Description | FUNCTION: Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles . As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability . May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis . Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transfer from NADH to cytochrome b5 reductase then to cytochrome b5, the ultimate electron donor that primes the active site for substrate reduction . . |
Accessions | ENST00000407981.6 H7BYZ9 A0A8Q3SHL7 ENST00000463976.1 H0YDX4 ENST00000694922.1 ENST00000443880.1 ENST00000366910.10 [Q5VT66-1] ENST00000694918.1 A0A8Q3SHG3 X6RIL1 ENST00000694919.1 Q5VT66 |